Recent Company News

• 04:21 AM ET Sep 30, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 02:57 AM ET Oct 01, 2026
  

  Almirall announces long-term disease control for up to five years in patients with moderate-to-severe atopic dermatitis treated with Lebrikizumab (€10.56, 0.00)

• 08:11 AM ET Sep 30, 2026
  

  New Phase 3B data show Lilly's EBGLYSS (lebrikizumab-lbkz) met its primary and secondary endpoints at Week 16 in the Phase 3B ADtouch study in people with moderate-to-severe hand and foot atopic dermatitis ($1184.63, 0.00)

• 01:03 AM ET Sep 30, 2026
  

  Almirall to show new data for its biologic treatments, lebrikizumab in AD and tildrakizumab in PsO at EADV 2026 (€10.32, 0.00)

• 04:15 AM ET Sep 01, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (70 total)

• 03:56 AM ET Aug 19, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (46 total)

• 04:19 AM ET Aug 18, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (50 total)

• 02:05 AM ET Aug 10, 2026
  

  Almirall enters collaboration with CrystalO for discovery and development of novel small molecules in medical dermatology (€10.84, 0.00)

• 05:51 AM ET Jul 24, 2026
  

  Transcript Intelligence: Almirall Q2 Earnings Guidance